Wagering on Unfinished Experiments—Prediction Markets and Clinical Trial Integrity
This Viewpoint discusses the potential impact on recruitment, retention, measurement, or evidence generation after a prediction market platform announced it would host betting on the outcomes of clinical trials and US Food and Drug Administration regulatory reviews, noting that policy action is needed to ensure that prediction markets do not undermine the public interest.
Authors
- Jay B. Lusk (ORCID: https://orcid.org/0000-0002-5728-8872)
- Ann Marie Návar (ORCID: https://orcid.org/0000-0002-6197-9860)
- Robert M. Califf (ORCID: https://orcid.org/0000-0003-0231-3724)
- Emily Claire O'Brien (ORCID: https://orcid.org/0000-0002-8257-7561)
Institutions
- Duke University (US)
- Duke Clinical Research Institute (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1001/jama.2026.19361
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.00